Abstract
BCR-ABL1 transcript numbers were monitored in 161 patients who started treatment with imatinib early after diagnosis of chronic myeloid leukaemia in chronic phase and achieved complete cytogenetic responses (CCyR). A confirmed doubling in BCR-ABL1/ABL1 transcript levels was found to be a significant factor for predicting loss of CCyR [relative risk (RR) 8.3, P < 0.0001] and progression to advanced phase (RR 0.07, P = 0.03) provided that the eventual BCR-ABL1/ABL1 transcript level exceeded 0.05%; increases that never exceeded 0.05% had no predictive value. The finding of a kinase domain mutation in a patient in CCyR, though rare, also predicted for loss of CCyR.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Benzamides
-
Biomarkers, Tumor / analysis*
-
Cytogenetic Analysis
-
Disease-Free Survival
-
Follow-Up Studies
-
Fusion Proteins, bcr-abl / analysis*
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myeloid, Chronic-Phase / diagnosis*
-
Leukemia, Myeloid, Chronic-Phase / drug therapy
-
Leukemia, Myeloid, Chronic-Phase / mortality
-
Multivariate Analysis
-
Mutation
-
Oncogene Proteins v-abl / analysis
-
Phosphotransferases / genetics
-
Piperazines / therapeutic use*
-
Protein Structure, Tertiary / genetics
-
Pyrimidines / therapeutic use*
-
Risk
-
Survival Rate
-
Transcription, Genetic
Substances
-
Antineoplastic Agents
-
Benzamides
-
Biomarkers, Tumor
-
Oncogene Proteins v-abl
-
Piperazines
-
Pyrimidines
-
abl-bcr fusion protein, human
-
Imatinib Mesylate
-
Phosphotransferases
-
Fusion Proteins, bcr-abl